Nls pharmaceutics announces launch of paid for named patient program with mazindol er for idiopathic hypersomnia, a serious sleep disorder with no approved treatment options in europe

Zurich, switzerland / accesswire / november 23, 2022 / nls pharmaceutics ltd. (nasdaq:nlsp), (nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has launched a paid for named patient program (npp) for patients suffering from idiopathic hypersomnia (ih).
NLSP Ratings Summary
NLSP Quant Ranking